Phase I study of docetaxel in combination with Gemcitabine as first line chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gatzemeier, U
Bildat, S
Harstrick, A
Eberhardt, W
Achterrath, W
Krauss, C
Wilke, HJ
机构：
[1] Rhone Poulenc Rorer, Cologne, Germany
[2] W German Canc Ctr, Essen, Germany
[3] Krankenhaus, Grosshansdorf, Germany
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
448
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [41] First line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: A multicenter phase II study
    Lo Dico, M.
    Vasile, E.
    Tibaldi, C.
    Antonuzzo, A.
    Di Marsico, R.
    Tartarelli, G.
    Fabbri, A.
    Mazzoni, E.
    Andreuccetti, M.
    D'Alessandro, M.
    Nacci, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 35 - 35
  • [42] Sequential carboplatin-gemcitabine (CG) and docetaxel (D) in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): A phase II trial.
    Murad, AM
    Guimaraes, RC
    Scalabrini-Neto, AO
    Papa, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 708S - 708S
  • [43] Phase II study of biweekly Gemcitabine and Docetaxel as first line treatment for advanced disease in elderly Non Small Cell Lung Cancer (NSCLC) patients
    Munoz-Langa, Jose
    Sanchez-Hernandez, Alfredo
    Gomez-Codina, Jose
    Esquerdo, Gaspar
    Catot, Silvia
    Macia, Sonia
    Juan, Oscar
    Giner, Vicente
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S700 - S701
  • [44] Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Dane, Faysal
    Isikdogan, Abdurrahman
    Ustaalioglu, Basak Oven
    Coskun, Ugur
    Yumuk, Perran Fulden
    Dogu, Gamze Gokoz
    Ozdemir, Nuriye Yildirim
    Sevinc, Alper
    Gumus, Mahmut
    Ozkan, Metin
    Yildiz, Ramazan
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    TUMORI JOURNAL, 2010, 96 (03): : 400 - 404
  • [45] Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Rizvi, N. A.
    Azzoli, C.
    Miller, V.
    Ng, K.
    Fiore, J.
    Chia, G.
    Brower, M.
    Heelan, R.
    Hawkins, M.
    Kris, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 390S - 390S
  • [46] Docetaxel followed by gemcitabine in the treatment of advanced non-small cell lung cancer: A phase I study
    Frassineti, GL
    Ibrahim, T
    Zoli, W
    Monti, M
    Ricotti, L
    Nanni, O
    Amadori, D
    TUMORI JOURNAL, 2002, 88 (02): : 99 - 103
  • [47] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Eleni M. Karapanagiotou
    Adrianni Charpidou
    Ifigenia Tzannou
    Kalliopi Dilana
    Elias Kotteas
    Ioannis Tourkantonis
    Epaminondas Kosmas
    Aspasia Provata
    Kostas Syrigos
    Medical Oncology, 2008, 25 : 303 - 308
  • [48] A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
    Goern, Michael
    Habermann, Christian R.
    Anige, Manuela
    Thoem, Ina
    Schuch, Gunter
    Andritzky, Birte
    Brandl, Stefan
    Burkholder, Iris
    Edler, Lutz
    Hossfeld, Dieter Kurt
    Bokemeyer, Carsten
    Laack, Eckart
    ONKOLOGIE, 2008, 31 (04): : 185 - 189
  • [49] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Karapanagiotou, Eleni M.
    Charpidou, Adrianni
    Tzannou, Ifigenia
    Dilana, Kalliopi
    Kotteas, Elias
    Tourkantonis, Ioannis
    Kosmas, Epaminondas
    Provata, Aspasia
    Syrigos, Kostas
    MEDICAL ONCOLOGY, 2008, 25 (03) : 303 - 308
  • [50] Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC)
    Ferrigno, D
    Buccheri, G
    LUNG CANCER, 2004, 45 (03) : 373 - 380
12345